Exparel has been shown to have better pain control compared to previously used infiltration
      agents, including bupivacaine, while having a minor side effect profile. The purpose of this
      study is to explore the effectiveness of Exparel (liposomal bupivacaine) in Adductor Canal
      Blocks for peri-operative pain control following a total knee arthroplasty (TKA) procedure.

Exparel Use in Adductor Canal Block After Total Knee Arthroplasty

Arthritis Knee

Pain, Postoperative

Opioid Use

The effectiveness of an Exparel Block (Bupivacaine Liposomal Injectable Suspension) for
      post-operative pain control has been well studied with encouraging results. At the
      investigators' institution, Exparel has been approved as a safe and effective option for use
      in shoulder surgeries and have had encouraging results in adductor canal use for pain control
      in patients undergoing TKA. Exparel has been shown to have better pain control compared to
      previously used infiltration agents, including bupivacaine, while having a minor side effect
      profile. The purpose of this study is to explore the effectiveness of Exparel (liposomal
      bupivacaine) in Adductor Canal Blocks (ACB) for peri-operative pain control following a total
      knee arthroplasty (TKA) procedure. Specifically, the investigators look to see if Exparel ACB
      reduces opioid requirement use post-operatively, reduces pain scores post-operatively,
      provides earlier mobilization, and decreases length of hospital stay.

Exparel

Ropivacaine

Adductor Canal Blocks Using Exparel for Pain Control After Total Knee Arthroplasty

Inpatient post-operative stay after undergoing TKA procedure

Opioid usage during their inpatient post-operative hospital stay

Measured with Numerical Rating Scale (Range: 0-10, Minimum:0, Maximum:10). Change in NRS Pain Score from pre-operative levels. Positive changes indicate a decrease in pain levels from pre-operative levels.

Opioid usage in the immediate post-operative period after hospital discharge

Western Ontario and McMaster Universities Osteoarthritis Index Patient Subjective Outcome Score (Range: 0-96, Minimum:0, Maximum:96). Subsections include Pain (Range:0-20, Minimum:0, Maximum:20), Stiffness (Range:0-8; Minimum:0, Maximum:8), and Functional Limitation (Range0-68, Minimum:0, Maximum:68). Measured as change in score from baseline levels. Positive scores indicate an improvement in WOMAC scores from pre-operative levels.

Principal Investigator

Rate of needing to be readmitted to the hospital secondary to inadequate pain control post-operatively at any point during the study period.

Rate of needing to be discharged to an inpatient rehabilitation facility after TKA procedure secondary to inadequate pain control and functional recovery

Liposomal Bupivacaine use as active ingredient in the block

Ropivacaine use as active ingredient in the block

Exparel Use in Adductor Canal Block After Total Knee Arthroplasty

About this trial

Study ID

Status

Type

Phase

Placebo

Accepting

Trial Timing

What is this trial about?

What are the participation requirements?

Locations

Location

Status